Heparinex, Novo Nordisk deal

Heparinex's Caisson Biotech LLC subsidiary granted Novo Nordisk exclusive rights to commercialize insulin conjugated to HEPtune heparosan-based drug delivery technology and non-exclusive rights to use the technology for additional indications, including diabetes, human growth hormone therapy, obesity and inflammatory diseases. Under the deal, Caisson is eligible for up to $167 million in an undisclosed upfront payment and milestone payments, plus royalties. Under a 2012 deal worth up to $100 million, Novo has exclusive rights to use HEPtune technology to develop compounds within undisclosed indications (see BioCentury, May 7, 2012). ...